Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP head

This article was originally published in The Tan Sheet

Executive Summary

FDA's Roger Williams, MD, appointed exec VP and CEO-designate of the U.S. Pharmacopeial Convention beginning Jan. 4. Williams succeeds Jerome Halperin, who announced his departure earlier this year. Williams has served as deputy director for pharmaceutical science at FDA's Center for Drug Evaluation & Research since 1995. He also has been acting director, Office of New Drug Chemistry, from 1995-1996; he also served as associate director for science and medical affairs and director of the Office of Generic Drugs. Williams, 58, is a member of WHO's Expert Committee on Specifications for Pharmaceutical Preparations and has maintained an adjunct faculty position at the University of California at San Francisco throughout his tenure with FDA

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS090424

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel